Our approach

The latest technological advances for a new generation of medicines

Each year, Ethypharm injects 15% of its turnover - 130 million Euros in 2010 - into R&D.  Such a level of investment is crucial, for it lets our company design, develop and produce new and particularly innovative medications.

Approach the future with customised technologies

To take advantage of the latest technological advances while benefiting from proven processes, Ethypharm applies a policy of active business intelligence on all worldwide markets. Our company has the ability to develop new products that guarantee patients that drugs are always safe, effective and innovative.

 

Our technologies can be applied to the majority of formulation issues encountered by pharmaceutical companies, whether by modifying the release profile (sustained, delayed or targeted release), improving bioavailability or masking the taste of active ingredients.